An Open-label Sunitinib Malate (su011248) Continuation Protocol For Patients Who Have Completed A Prior Sunitinib Study And Are Judged By The Investigator To Have The Potential To Benefit From Sunitinib Treatment
An Open-label Sunitinib Malate (su011248) Continuation Protocol For Patients Who Have Completed A Prior Sunitinib Study And Are Judged By The Investigator To Have The Potential To Benefit From Sunitinib Treatment
This is a study using sunitinib for patients ending treatment on a previous sunitinib malate protocol to continue to receive sunitinib. The patient must have been enrolled in one of the following studies: A6181030, A6181064, A6181078, A6181087, A6181094, A6181107, A6181108, A6181110, A6181111, A6181112, A6181113, A6181120, A6181126 and A6181170. Other Pfizer sponsored sunitinib studies may be included in the future.
Inclusion Criteria:
Exclusion Criteria:
St Louis, Missouri 63110, United States
Fort Worth, Texas 76177, United States
Norfolk, Virginia 23510, United States
Nueva Cordoba, Nueva Cordoba X5006HBF, Argentina
Leuven, B-3000, Belgium
Lübeck, 23538, Germany
München, 81675, Germany
Tuen Mun, New Territories, Hong Kong
Monterrey, Nuevo León 64460, Mexico
Seoul, Republic of Korea 110-744, South Korea
Seoul, Republic of Korea 138-736, South Korea
Seoul, 120-752, South Korea
Kaohsiung City, 807, Taiwan